8-K filed Nov 2, 2026 at 07:15 ET
uniQure announced that the FDA has accepted for review its Biologics License Application (BLA) for ifezuntirgene inilparvovec, an investigational gene therapy for Huntington's disease, under the Accelerated Approval pathway with Priority Review and a PDUFA target action date of May 1, 2027. The FDA is tentatively planning an Advisory Committee meeting, and the company has aligned with the FDA on a confirmatory study design. This is a significant regulatory milestone for a first-in-class therapy in an area with no approved disease-modifying treatments.